VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update – Markets Insider
Posted: July 1, 2017 at 2:46 am
SOUTH SAN FRANCISCO, CA--(Marketwired - June 29, 2017) - VistaGen Therapeutics Inc.(NASDAQ: VTGN), a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders, today reported its financial results for its fiscal year ended March 31, 2017.
The Company also provided an update on its corporate progress, clinical status and anticipated milestones for AV-101, its orally available CNS prodrug candidate in Phase 2 development, initially as a new generation treatment for major depressive disorder (MDD).
"With a team of industry experts and a focused strategy in place, we have established a strong foundation and embarked on paths to achieve several key catalysts within the next 18 months. We anticipate our first catalyst within the next 9 months as the NIMH completes its AV-101 Phase 2 monotherapy study in MDD, a study being conducted and fully funded by the NIH. Additionally, we are working closely with the FDA and our Principal Investigator, Dr. Maurizio Fava of Harvard University Medical School, on our AV-101 Phase 2 adjunctive treatment study in MDD, which we anticipate will begin enrollment in the first quarter of 2018 and be completed by the end of 2018, with topline results available in the first quarter of 2019," commented Shawn Singh, Chief Executive Officer of VistaGen.
In addition to MDD, AV-101 may have therapeutic potential in several other CNS indications where modulation of NMDA receptors, activation of AMPA pathways and/or active metabolites of AV-101 play a key role, including for treatment of epilepsy, as a non-opioid alternative for management of neuropathic pain, and to address certain symptoms associated with Parkinson's disease and Huntington's disease.
Mr. Singh continued, "Our MDD clinical program is our top priority, and will remain so. Additionally, however, recent peer-reviewed publications suggest that AV-101 may have significant therapeutic potential as a non-opioid treatment alternative for pain management. We are also excited about AV-101's potential to reduce dyskinesia associated with standard levodopa, or L-DOPA, therapy for Parkinson's disease, based on results from previous non-clinical studies. Without diverting our priority focus on MDD, we plan to expand our AV-101 Phase 2 clinical program during the next year to include these important CNS indications with significant unmet need."
"We are also pleased to have advanced our cardiac stem cell program during fiscal 2017, through both our participation in the FDA's CiPA initiative focused on using novel human stem cell models to predict cardiac toxicity of new drug candidates long before animal and human studies, as well as our exclusive sublicense agreement with BlueRock Therapeutics, an emerging force in cardiac regenerative medicine, founded and funded by Bayer AG and Versant Ventures. Our initial revenue-generating milestone with BlueRock Therapeutics was completed during fiscal 2017. We are optimistic about this relationship's potential and the future of cardiac regenerative medicine. We believe these significant events over the past year have positioned us to create substantial value for our stakeholders in fiscal 2018 and beyond."
Potential Near-Term Milestones:
Operational Highlights During Fiscal 2017:Achievements Related to Stem Cell Technologies
Advancement of AV-101 as a Potential, Non-Opioid Treatment Alternative for Chronic Pain
Bolstered Team with Industry Experts
Intellectual Property Accomplishments
Capital Market Highlights
Financial Results for the Fiscal Year Ended March 31, 2017:
Revenue for the fiscal year ended March 31, 2017 totaled $1.25 million and was attributable to a sublicense agreement with BlueRock Therapeutics, for certain rights to the Company's proprietary technologies relating to the production of cardiac stem cells for the treatment of heart disease.
Research and development expense totaled $5.2 million for the fiscal year ended March 31, 2017, an increase of approximately 33% compared with the $3.9 million incurred for the fiscal year ended March 31, 2016. The increase in year-over-year research and development expense was attributable to increased focus on development of AV-101, including preparations to launch the Phase 2 Adjunctive Treatment Study in MDD.
General and administrative expense decreased to $6.3 million in the fiscal year ended March 31, 2017, from $13.9 million in the fiscal year ended March 31, 2016, primarily as a result of the decrease in non-cash stock compensation expense, partially offset by an increase in non-cash expense related to grants of equity securities in payment of certain professional services during fiscal 2017. Of the amounts reported, non-cash expenses, related primarily to grants or modifications of equity securities, totaled approximately $3.1 million in fiscal 2017 and $11.9 million in fiscal 2016.
Net loss for the fiscal years ended March 31, 2017 and 2016 was approximately $10.3 million and $47.2 million, respectively, the latter amount including a non-recurring, non-cash expense of approximately $26.7 million attributable to the extinguishment of approximately $15.9 million carrying value of prior indebtedness, including then-outstanding Senior Secured Convertible Notes, and conversion of such indebtedness into equity securities between May and September 2015 at a conversion price (stated value of the equity received) of $7.00 per share.
At March 31, 2017, the Company had a cash and cash equivalents balance of $2.9 million. Since late-March 2017, the Company sold units consisting of unregistered common stock and common stock warrants to accredited investors in a self-placed private placement, yielding approximately $1 million in cash proceeds to the Company.
About VistaGen
VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company focused on developing new generation medicines for depression and other central nervous system (CNS) disorders. VistaGen's lead CNS product candidate, AV-101, is in Phase 2 development, initially as a new generation oral antidepressant drug candidate for major depressive disorder (MDD). AV-101's mechanism of action is fundamentally differentiated from all FDA-approved antidepressants and atypical antipsychotics used adjunctively to treat MDD, with potential to drive a paradigm shift towards a new generation of safer and faster-acting antidepressants. AV-101 is currently being evaluated by the U.S. National Institute of Mental Health (NIMH) in a Phase 2 monotherapy study in MDD being fully funded by the NIMH and conducted by Dr. Carlos Zarate Jr., Chief, Section on the Neurobiology and Treatment of Mood Disorders and Chief of Experimental Therapeutics and Pathophysiology Branch at the NIMH. VistaGen is preparing to launch a 180-patient Phase 2 study of AV-101 as an adjunctive treatment for MDD patients with inadequate response to standard, FDA-approved antidepressants. Dr. Maurizio Fava of Harvard University will be the Principal Investigator of the Company's Phase 2 adjunctive treatment study. AV-101 may also have the potential to treat multiple CNS disorders and neurodegenerative diseases in addition to MDD, including neuropathic pain, epilepsy, Huntington's disease, L-Dopa-induced dyskinesia associated with Parkinson's disease and other disorders where modulation of the NMDA receptors, activation of AMPA pathways and/or key active metabolites of AV-101 may achieve therapeutic benefit.
VistaStem Therapeutics is VistaGen's wholly owned subsidiary focused on applying human pluripotent stem cell technology, internally and with collaborators, to discover, rescue, develop and commercialize proprietary new chemical entities (NCEs), including small molecule NCEs with regenerative potential, for CNS and other diseases, and cellular therapies involving stem cell-derived blood, cartilage, heart and liver cells.
For more information, please visit http://www.vistagen.com and connect with VistaGen on Twitter, LinkedIn and Facebook.
Forward-Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the successful financing, launch, continuation and results of the NIMH's Phase 2 (monotherapy) and/or the Company's planned Phase 2 (adjunctive therapy) clinical studies of AV-101 in MDD, and other CNS diseases and disorders, including neuropathic pain and L-DOPA-induced dyskinesia associated with Parkinson's disease, protection of its intellectual property, and the availability of substantial additional capital to support its operations, including the Phase 2 clinical development activities described above. These and other risks and uncertainties are identified and described in more detail in VistaGen's filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC's website at http://www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.
FINANCIAL TABLES FOLLOW
Read the rest here:
VistaGen Therapeutics Reports Fiscal 2017 Financial Results and Provides Corporate Update - Markets Insider
- The Beating Heart (Cardiac) Cells [Last Updated On: June 24th, 2011] [Originally Added On: June 24th, 2011]
- cellalign [Last Updated On: June 24th, 2011] [Originally Added On: June 24th, 2011]
- Okamoto placenta-derived cardiomyocytes [Last Updated On: June 25th, 2011] [Originally Added On: June 25th, 2011]
- Cardiac Stem Cell Therapy [Last Updated On: June 26th, 2011] [Originally Added On: June 26th, 2011]
- Wow! UW Research labs [Last Updated On: June 26th, 2011] [Originally Added On: June 26th, 2011]
- Cardiac Stem Cell Therapy [Last Updated On: June 28th, 2011] [Originally Added On: June 28th, 2011]
- cellalign [Last Updated On: July 3rd, 2011] [Originally Added On: July 3rd, 2011]
- Insidermedicine In 60 - August 4, 2011 [Last Updated On: August 25th, 2011] [Originally Added On: August 25th, 2011]
- Cardiac Stem Cells in End-Stage Human Failing Hearts: Are they functional? [Last Updated On: August 28th, 2011] [Originally Added On: August 28th, 2011]
- Did you have a Heart Attack and Need to Recover your Cardiac Muscle? [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Heart repair using own stem cells after heart attack: Future Health keynote speaker [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Cardiac Stem Cell Therapy at Rostock University [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Cardiovascular Therapies: Spotlight on Stem Cell Research - Douglas Boyd [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Davos Question: Stem Cell Answer [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Stem Cell operation in Cardiac Surgery-Al-Jazeerah [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Stem Cell Therapy in Cardiac Disease [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Designer Life: repair brain, heart with stem cells - Future Health keynote speaker [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- Stem Cells: Mending a broken heart? [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- Cardiac Stem Cells in End-Stage Human Failing Hearts: Are they functional? [Last Updated On: September 8th, 2011] [Originally Added On: September 8th, 2011]
- Oral Surgeon utilizes StemSave to preserve stem cells in wisdom teeth to combat cardiac disease [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- Cardiac Recovery Points to Adult Stem Cells [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- Oral Surgeon utilizes StemSave to preserve stem cells in wisdom teeth to combat cardiac disease [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Stem Cell operation in Cardiac Surgery-Al-Jazeerah [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Cardiovascular Derivatives of Embryonic Stem Cells in Cardiac Repair and Drug Discovery [Last Updated On: September 10th, 2011] [Originally Added On: September 10th, 2011]
- Stem Cell Therapy in Cardiac Disease [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- Cardiovascular Derivatives of Embryonic Stem Cells in Cardiac Repair and Drug Discovery [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Stem Cells and Cardiac Regeneration [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Cardiomyogenic differentiation of Mesenchymal Stem cells (KUM2/9-15c) [Last Updated On: September 12th, 2011] [Originally Added On: September 12th, 2011]
- Mark Mercola: Differentiating embryonic stem cells into adult tissues [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- Cardiovascular Therapies: Spotlight on Stem Cell Research - Douglas Boyd [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Stem Cell #8 Vas Cath Removal 04/28/11 [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Adult Stem Cells Used To Rebuild Heart Tissue Video. More at http://www.stemcellfusion.com [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Stem Cell Therapy and Stem Cell Treatment with Dell [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- First US Patient In Stem Cell Transplant [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Stem Cell Heart Surgery must see [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Beating cardiac myocytes from differentiated mouse iPSC. [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- heart cell generation from human ES and iPS cells (embryonic and induced pluripotent stem cells).flv [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Advanced Cell Technology OneMedForum 2011 [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- 20100804_axiogenesis.wmv [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Pt. 1--Dr. Ali Denktas--Stem Cells as Markers after Myocardial Infarctions [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Cardiac Tissue Can Regenerate [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Adult Stem Cell [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Beating cardiomyocyte monolayer [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Valentine's Day Stem Cell Wish: Mending Broken Hearts [Last Updated On: September 23rd, 2011] [Originally Added On: September 23rd, 2011]
- Cardiomyocytes derived from mouse Embryonic stem cells [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- UCD Med Student Receives Fulbright Award [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Mouse GEN cells overexpressing Csx/Nkx2.5 and GATA4 behave like transient amplifying cells [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- 2010 - 2011 UConn Highlight Reel [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- William F. Testimonial of Treatment Stem Cell [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- BeatingCM_on_MEA.wmv [Last Updated On: September 24th, 2011] [Originally Added On: September 24th, 2011]
- Breakthrough in Stem cell technology [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- stem cell derived cardiomyocytes [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Mark Mercola: Differentiating embryonic stem cells into adult tissues [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Cadiomyogenesis of human mesenchymal stem cells [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Adult Stem Cell vs Embryonic Stem Cell Research Ethics Video [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Heart Failure Patient After Adult Stem Cell Therapy [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Affordable Stem Cell Therapy in Guatemala (2hrs from Miami) [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Kevin's 2 Heart Transplants and Stem Cell Transplant [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Immune Control of Stem Cell Mobilization [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Patel Stem Cell Heart Failure [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Better Drugs Through Stem Cells [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Heart Disease Patient Describes His Stem Cell Treatment [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Turning Adult Stem Cells into Medicine - Zannos Grekos, MD [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- Cardiomyocytic differentiation of endometrial stem cells. [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Turning Adult Stem Cells into Medicine - Zannos Grekos, MD [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Stem Cells: Heart cells grown from mouse stem cells [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Beating cells [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- Repairing Damaged Hearts with Stem Cells [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- Heart cells grown from human embryonic stem cells [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- CytoTune iPSCs - Cardiomyocytes [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- Becoming Bionic: The Little Book of Hope for Heart Patients Runblog ("Dress the Part") [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- H9 Cardiac EBs.mov [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- Beating Cardiomyocytes from E14 Cells [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- Human 2.0: The Helix of Our Future [Last Updated On: September 30th, 2011] [Originally Added On: September 30th, 2011]
- Beating Human Heart Cells from Embryonic Stem Cells [Last Updated On: October 1st, 2011] [Originally Added On: October 1st, 2011]
- Be still my beating stem cell heart [Last Updated On: October 1st, 2011] [Originally Added On: October 1st, 2011]
- Doctors To Use 'Trained' Stem Cells To Heal Heart [Last Updated On: October 2nd, 2011] [Originally Added On: October 2nd, 2011]
- Spontaneously and rhythmically beating engineered human heart tissue from pluripotent stem cells [Last Updated On: October 3rd, 2011] [Originally Added On: October 3rd, 2011]
- Cardiac Stem Cell Therapy - How it works [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Doctors To Use 'Trained' Stem Cells To Heal Heart [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]